drugset / Trial / NCT03219450
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Phase 1
Recruiting
15 enrolled
Dana-Farber Cancer Institute
BioNTech SE · collabMerck Sharp & Dohme LLC · collabOncovir, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This research study is studying a novel type of CLL vaccine as a possible treatment for chronic lymphocytic leukemia (CLL) The names of the study interventions involved in this study are: * Personalized NeoAntigen Vaccine * Poly-ICLC * Cyclophosphamide * Pembrolizumab
Timeline
- Start
- 2021-08-18
- Primary completion
- 2027-07-31
- Completion
- 2028-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | NeoVax | Vaccine | — | Subcutaneous |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |